Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> Following infliximab, FC and CRP declined (<i>p</i> < .0001) along with HBi for CD and pMCS for UC.
|
31499013 |
2019 |
Crohn Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Disease behavior/presence of steroid exposure and elevated CRP were associated with hospitalization among CD and UC patients who visited the ED, respectively.
|
30650133 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The Crohn's Disease Activity Index (CDAI), fecal calprotectin, C-reactive protein levels, antibodies (ATI), and trough level (TLI) of IFX were measured at every IFX infusion.
|
28002129 |
2017 |
Crohn Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The CRP GRSGWAS showed that a 10% increase in genetically determined CRP level was significantly associated with coronary artery disease (OR 0.88 [95% CI 0.84-0.94]; p < 2.4 × 10-5) and was nominally associated with the risk of inflammatory bowel disease (OR 0.85 [95% CI 0.74-0.98]; p < 0.03), Crohn disease (OR 0.81 [95% CI 0.70-0.94]; p < 0.005), psoriatic arthritis (OR 1.36 [95% CI 1.00-1.84]; p < 0.049), knee osteoarthritis (OR 1.17 [95% CI 1.01-1.36]; p < 0.04), and bipolar disorder (OR 1.21 [95% CI 1.05-1.40]; p < 0.007) and with an increase of 0.72 (95% CI 0.11-1.34; p < 0.02) mm Hg in systolic blood pressure, 0.45 (95% CI 0.06-0.84; p < 0.02) mm Hg in diastolic blood pressure, 0.01 ml/min/1.73 m2 (95% CI 0.003-0.02; p < 0.005) in estimated glomerular filtration rate from serum creatinine, 0.01 g/dl (95% CI 0.0004-0.02; p < 0.04) in serum albumin level, and 0.03 g/dl (95% CI 0.008-0.05; p < 0.009) in serum protein level.
|
27327646 |
2016 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize the interpretation of CRP and FC in patients with CD within specific clinical contexts and according to assay performance characteristics.
|
31327404 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the diagnostic performance as well as the relationship of C-reactive protein (CRP) and Crohn's Disease Activity Index (CDAI) with small bowel capsule endoscopy's (SBCE) inflammation scoring index, the Lewis Score (LS).
|
29697457 |
2018 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CLE<sup>+</sup> patients showed an increased incidence of medical treatment escalation (P < .001; relative risk [RR] = 3.27) and transmural lesions (P = .025; RR = 1.70), whereas patients with CRP ≥5 mg/L had increased CD-related hospitalization and surgery (P = .020, RR = 2.71) at 1-year follow-up.
|
29108979 |
2018 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
At week 44 of the maintenance study (52 weeks after treatment began), patients were evaluated for the primary endpoint of clinical remission (defined as a CD activity index score below 150 points), endoscopic markers of efficacy, and serum level of C-reactive protein.
|
29409871 |
2018 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These cytokines and CRP may serve as additional biomarkers for determining disease activity and evaluating treatment response in CD.
|
29466406 |
2018 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Secondary outcomes included: the proportion of patients who responded to the reintroduction of immunosuppressant or biologic drugs, given as monotherapy or combination therapy; the proportion of patients who required surgery following relapse; the proportion of patients who required hospitalization for CD following relapse; the proportion of patients who developed new CD-related complications (e.g. fistula, abscesses, strictures) following relapse; the proportion of patients with elevated biomarkers of inflammation (CRP, fecal calprotectin) in those who stop and those who continue therapy; the proportion of patients with anti-drug antibodies and low serum trough drug levels; time to relapse; and the proportion of patients with adverse events, serious adverse events and withdrawal due to adverse events.
|
29756637 |
2018 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Simulated CZP concentrations were compared to outcomes at weeks 6 and 26, including Crohn's disease activity index (CDAI) response (decrease from baseline ≥ 100 points), remission (CDAI ≤ 150), C-reactive protein (CRP) ≤ 5 mg/L, faecal calprotectin (FC) ≤ 250 μg/g, and a composite endpoint of CDAI ≤ 150 and FC ≤ 250 μg/g.
|
29159893 |
2018 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum 25(OH)D<sub>3</sub> was inversely correlated with faecal calprotectin (FC) for CD and UC but was only correlated with C-reactive protein (CRP) for UC patients.
|
31083541 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We performed a nonblinded, randomized controlled trial of 78 children with CD (6-18 years old; 29% female; mean age, 14.3 ± 2.6 years) who had not received prior treatment with a biologic agent but had responded to adalimumab induction therapy, under scheduled monitoring of clinical and biologic measures (based on clinical factors and levels of C-reactive protein and fecal calprotectin), at pediatric gastroenterology units in Israel from July 2015 through December 2018.
|
31194979 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Emerging evidence indicates that CRP and FC are valuable adjuncts for the management of CD in specific circumstances described in this review.
|
30791776 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Fift y-three adult patients with proven CD underwent magnetic resonance enterocolonography (MR-EC), colonoscopy, and clinical activity assessment, including CRP.
|
31737782 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The variables used were Crohn's disease activity index (CDAI), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR).
|
31689999 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRP at biologic introduction and age at CD onset predicted LOR.
|
28422861 |
2017 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
FC is not better than CRP combined with HBI to predict endoscopic postoperative recurrence of CD.
|
30303822 |
2018 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A high IL-6 concentration on POD 1 is independently associated with the occurrence of postoperative IASCs in patients undergoing elective surgery for CD and could allow for earlier diagnosis and earlier intervention for IASCs compared with C-reactive protein.
|
29912382 |
2018 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of the present study was to explore the correlations between LS and clinical disease activity indices, CRP, SBTT in pediatric, and adult patients with small bowel CD.Retrospective, single-center study on consecutive inpatients with established small bowel CD was conducted.
|
28816962 |
2017 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Even when CD patients are in clinical remission, elevated CRP is significantly associated with subsequent CD-related hospitalization and CD-related intestinal resection during follow-up.
|
28622356 |
2017 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TRIM22 is also associated with antiviral and mycobacterial effectors and markers of inflammation, such as fecal calprotectin, C-reactive protein, and Crohn's disease activity index scores.
|
26836588 |
2016 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim was to assess the value of C-reactive protein and TNF-alpha serum levels before treatment as well as the TNF -308 gene polymorphism in the prediction of response to infliximab treatment in Crohn disease.
|
12190096 |
2002 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inclusion criteria included: a diagnosis of ulcerative colitis or Crohn's disease with objective evidence of active inflammation at baseline (Harvey-Bradshaw Index[HBI] ≥5/Partial Mayo ≥2 plus C-reactive protein [CRP] >5 mg/L or faecal calprotectin ≥250 µg/g or inflammation on endoscopy/magnetic resonance imaging [MRI]); completion of induction; and at least one clinical follow-up by 12 months.
|
30768123 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elderly patients with CD and patients with normal pretreatment CRP level may have a reduced response to MTX.
|
30516330 |
2018 |